Furthermore, METTL3 small interfering RNAs and RIP assay indicated that cyclin-dependent kinase inhibitor 2A (CDKN2A) was a key regulator in CTCL, and insufficient methylation blocked the interaction between CDKN2A and m6A reader IGF2BP2, resulting in mRNA degradation [68]. Here, CDKN2A is linked to primary cutaneous T-cell non-Hodgkin lymphoma.